Pramipexole

Research use only, not for human use.

A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively.

A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively; also possesses low/insignificant affinity (500–10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors; used for treating Parkinson's disease (PD) and restless legs syndrome (RLS).Parkinson's Disease Approved.

Pramipexole shows a low binding affinity for D1-type receptor, with an IC50 of >50,000 nM.Pramipexole (0.01-10?μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size.Pramipexole attenuates levodopa-induced toxicity in mesencephalic cultures.

Pramipexole (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals.Pramipexole improves neurological recovery.Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Animal Model:Male Wistar rats weighing 250-300 g (16-18 weeks old)Dosage:0.25 mg/kg, 1 mg/kg Administration:Intraperitoneal injection Result:Decreased infarction volume as compared to tMCAO (transient middle cerebral artery occlusion)-only animals.

Pramipexole | Oprymea | Pramipexol | Pramipexolum

GPCR/G Protein

Dopamine Receptor

D2L|D3|D4

Neurological Disease

Parkinson Disease

104632-26-0

211.3271

C10H17N3S

>98% (HPLC)

10 mM in DMSO

CCCN[C@H](C1)CCC2=C1SC(N)=N2

2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (6S)-

(-20℃)

With Ice Pack

≥ 2 years